APA
Larsen J. R., Svensson C. K., Vedtofte L., Jakobsen M. L., Jespersen H. S., Jakobsen M. I., Koyuncu K., Schjerning O., Nielsen J., Ekstrøm C. T., Holst J. J., Correll C. U., Vilsbøll T. & Fink-Jensen A. (2019). High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. : CNS spectrums.
Chicago
Larsen Julie R, Svensson Camilla K, Vedtofte Louise, Jakobsen Mathilde Lund, Jespersen Hans Søe, Jakobsen Michelle I, Koyuncu Kamuran, Schjerning Ole, Nielsen Jimmi, Ekstrøm Claus T, Holst Jens J, Correll Christoph U, Vilsbøll Tina and Fink-Jensen Anders. 2019. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. : CNS spectrums.
Harvard
Larsen J. R., Svensson C. K., Vedtofte L., Jakobsen M. L., Jespersen H. S., Jakobsen M. I., Koyuncu K., Schjerning O., Nielsen J., Ekstrøm C. T., Holst J. J., Correll C. U., Vilsbøll T. and Fink-Jensen A. (2019). High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. : CNS spectrums.
MLA
Larsen Julie R, Svensson Camilla K, Vedtofte Louise, Jakobsen Mathilde Lund, Jespersen Hans Søe, Jakobsen Michelle I, Koyuncu Kamuran, Schjerning Ole, Nielsen Jimmi, Ekstrøm Claus T, Holst Jens J, Correll Christoph U, Vilsbøll Tina and Fink-Jensen Anders. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. : CNS spectrums. 2019.